Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Bicalutamide in Scrotal Paget's Disease
NCT07117851Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in extramammary Paget disease (EMPD), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 weeks. Started Aug 2025; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
extramammary Paget disease (EMPD)
Beyond the preview
Go deeper on NCT07117851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117851.